Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | NOS3 | P29474 | 1/20 | 0.53 |
| ▸ | NOS1 | P29475 | 1/20 | 0.53 |
| ▸ | NOS2 | P35228 | 1/20 | 0.53 |
| ▸ | PLAU | P00749 | 2/20 | 0.53 |
| ▸ | CCR1 | P32246 | 1/20 | 0.52 |
| ▸ | CCR5 | P51681 | 1/20 | 0.52 |
| ▸ | CCR8 | P51685 | 1/20 | 0.52 |
| ▸ | PARP1 | P09874 | 2/20 | 0.49 |
| ▸ | HPGDS | O60760 | 1/20 | 0.46 |
| ▸ | GRM5 | P41594 | 1/20 | 0.46 |
| ▸ | NNMT | P40261 | 1/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.46 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.46 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | PKM | P14618 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1023538 | 0.83 | ALDH1A1 (0.55) | KDM4ENOS3NOS1NOS2PLAU | |
| SCHEMBL2915719 | 0.83 | CCR1 (0.53) | KDM4ENOS3NOS1NOS2PLAU | |
| SCHEMBL29455922 | 0.83 | ALDH1A1 (0.55) | KDM4ENOS3NOS1NOS2PLAU | |
| SCHEMBL11617771 | 0.82 | PARP10 (0.51) | KDM4ENOS1NOS2PARP10RAB9A | |
| SCHEMBL30438262 | 0.82 | PARP10 (0.51) | KDM4ENOS1NOS2PARP10RAB9A | |
| Hydrochloric Acid SCHEMBL6640953 | 0.81 | ALDH1A1 (0.53) | KDM4ENOS3NOS1NOS2PLAU | |
| SCHEMBL28957013 | 0.81 | ALDH1A1 (0.53) | KDM4ENOS3NOS1NOS2PLAU | |
| SCHEMBL1703544 | 0.81 | CCR1 (0.52) | KDM4ENOS3NOS1NOS2PLAU | |
| SCHEMBL31175929 | 0.81 | CCR1 (0.52) | KDM4ENOS3NOS1NOS2PLAU | |
| SCHEMBL16211028 | 0.81 | CCR1 (0.52) | KDM4ENOS3NOS1NOS2PLAU |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 245 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-22 | — | — | US | claimed |
| EP-1884513-A1 | PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME | Japan Tobacco, Inc. (JP) | 2008-02-06 | — | — | EP | claimed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | claimed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | claimed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | claimed |
| WO-2026087745-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-30 | — | — | WO | disclosed |
| EP-4732825-A1 | AN ANTIOXIDANT COMPOSITION COMPRISING A CINNAMIC ACID DERIVATIVE | BRAIN Biotech AG (DE) | 2026-04-29 | — | — | EP | disclosed |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | SYMRISE AG (DE) | 2026-04-09 | — | — | US | disclosed |
| EP-4025675-B1 | A PERFUME OIL MIXTURE | SYMRISE AG (DE) | 2026-03-18 | — | — | EP | disclosed |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | SYMRISE AG (DE) | 2026-02-19 | — | — | US | disclosed |
| US-20260041094-A1 | Compositions Comprising an Antimicrobial Boosting Agent | SYMRISE AG (DE) | 2026-02-12 | — | — | US | disclosed |
| EP-4687810-A1 | PREPARATIONS COMPRISING HYDROXY PINACOLONE RETINOATE | Symrise AG (DE) | 2026-02-11 | — | — | EP | disclosed |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | JAPAN TOBACCO INC. (JP) | 2007-02-08 | — | — | US | disclosed |
| US-7148242-B2 | N-formyl hydroxylamine compounds, compositions and methods of use | NOVARTIS AG (CH) | 2006-12-12 | — | — | US | disclosed |
| EP-1401828-B1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARM INC (US) | 2006-04-12 | — | — | EP | disclosed |
| EP-1401828-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | Vicuron Pharmaceuticals, Inc. (US) | 2004-03-31 | — | — | EP | disclosed |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | VICURON HOLDINGS LLC | 2003-03-06 | — | — | US | disclosed |
| WO-2002102790-A1 | N-FORMYL HYDROXYLAMINE COMPOUNDS AS INHIBITORS OF PDF | VICURON PHARMACEUTICALS INC. (US) | 2002-12-27 | — | — | WO | disclosed |
| US-4855420-A | Cephalosporin derivatives | ICI PHARMA (FR) | 1989-08-08 | — | — | US | disclosed |
| US-4678781-A | BACTERICIDAL ANTIBIOTICS | ICI PHARMA (FR) | 1987-07-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110312935-A1 | 1H-Benz Imidazole-5-Carboxamides As Anti-Inflammatory Agents | MAPRE2, MAPRE1, H1-4 | KDM4E 140/4885NOS3 187/4885NOS1 432/4885 |
| US-20030045479-A1 | Novel N-formyl hydroxylamine compounds, compositions and methods of use | PDF, HNMT, AADAC | KDM4E 2350/4885NOS3 1675/4885NOS1 1951/4885 |
| US-20260041094-A1 | Compositions Comprising an Antimicrobial Boosting Agent | TLR7, MYC, ERG28 | KDM4E 4297/4885NOS3 149/4885NOS1 196/4885 |
| US-20260047994-A1 | AN ACTIVE COMPOSITION COMPRISING RETINOL | RBP4, LRAT, RARB | KDM4E 1000/4885NOS3 3438/4885NOS1 4185/4885 |
| US-20070032529-A1 | Pyrazole compounds and their use as antidiabetes agents | PYGL, GYS2, AGL | KDM4E 3446/4885NOS3 2959/4885NOS1 4311/4885 |
| US-20260096978-A1 | A METHOD FOR PREVENTING, MITIGATING AND/OR TREATING PTGS2-INDUCED SKIN DISORDERS AND RELATED DYSFUNCTIONS | PTGS2, PTGES2, PTGS1 | KDM4E 4565/4885NOS3 38/4885NOS1 61/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.